Quality of life and productivity loss in patients with ankylosing spondylitis using tumor necrosis factor inhibitorsDear Editor,We have read with great interest the article by Lee et al 1 reporting a comprehensive understanding of the real-world treatment patterns of tumor necrosis factor inhibitor (TNFi) in patients with ankylosing spondylitis (AS) and productivity loss, treatment satisfaction, and associated factors. There are 4 TNFi considered in this study, including infliximab, adalimumab, etanercept, and golimumab. The advantage of this study was that the data collected is extremely detailed and novel, including annual household income, education, and body mass index, which helps us know more about this issue from a different perspective and may arouse much attention to the issue that has usually been neglected previously. However, we found some concerns that we hope to be answered.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.